The initial results of the ANRS VRI06 Phase I trial of a preventive HIV vaccine conducted by Inserm-ANRS and the Vaccine Research Institute (ANRS and Université Paris-Est Créteil) reveal that the vaccine candidate is safe and induces an early, significant and lasting immune response. These results were presented on February 21, 2023 at the international Conference on Retroviruses and Opportunistic Infections (CROI), which took place on February 19–22 in Seattle and online.
Although these preliminary results are encouraging, it is important to note that the efficacy of the vaccine has yet to be demonstrated.
Read the full announcement here.
Source : ANRS | Emerging Infectious Diseases
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.